AIM ImmunoTech announces first COVID-19-induced chronic fatigue ‘Long Hauler’ patient dosed with Ampligen

AIM ImmunoTech announces first COVID-19-induced chronic fatigue ‘Long Hauler’ patient dosed with Ampligen

Proactive Investors

Published

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has announced Wednesday that the active AMP-511 Expanded Access Program (EAP) has dosed its first coronavirus (COVID-19) “Long Hauler” patient with the drug Ampligen (rintatolimod).  The company said the initial dosing marks a significant milestone in its efforts to develop an effective therapeutic for people suffering from post-COVID-19 infection chronic fatigue-like symptoms. Additional patients are in the process of being enrolled.  Meanwhile, the company also reported it will host an investor conference call on January 12 at 11 am ET to discuss the AMP-511 trial, believed to be the first clinical trial to treat a patient with COVID-19-induced chronic fatigue-like symptoms, as well as to provide an overall status update on the company.  READ: AIM ImmunoTech enrolling patients in coronavirus-induced chronic fatigue trial of Ampligen The Ampligen EAP protocol is authorized at any one time to enroll up to 100 active Chronic Fatigue Syndrome trial participants, 20 of whom may be Long Haulers. All study subjects will receive the same Ampligen treatments.  The EAP is being conducted by investigators Dr Charles Lapp at Hunter-Hopkins Center in Charlotte, North Carolina, and Dr Daniel Peterson at Sierra Internal Medicine in Incline Village, Nevada. “AIM is committed to helping the untold number of people who are already dealing with the long-term effects of COVID-19 infection,” said AIM CEO Thomas Equels in a statement. “The development of an effective therapy for COVID-19-induced chronic fatigue is a critical unmet public health need. SARS-CoV-2 infection-induced chronic fatigue may affect millions in the aftermath of the pandemic. Although AMP-511 is not a controlled trial, patients in this AIM-sponsored study are monitored closely and it may be possible to report important observations as early as May.” Dr Lapp added: “Hunter-Hopkins Center is excited to have started Ampligen therapy for the first time on a Long Hauler with CFS-like symptoms. This is a historic moment. We believe that Long Haulers experience a post-viral fatigue syndrome similar to many persons with Chronic Fatigue Syndrome, and starting treatment early and aggressively should enhance the potential to improve their symptoms and outcomes.” Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham

Full Article